{"filing":{"accession_number":"0001193125-26-282715","cik":"0001953530","ticker":"OCSAW","company_name":"Oculis Holding AG","form":"6-K","filing_date":"2026-06-25","report_date":null,"primary_document":"6-k_-_june_2026_corp_dec.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1953530/000119312526282715/6-k_-_june_2026_corp_dec.htm"},"events":[{"id":13845,"run_id":12299,"accession_number":"0001193125-26-282715","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"This exhibit is a corporate presentation (investor deck) dated June 2026 disclosing Oculis' clinical development pipeline, preclinical and Phase 2 trial data for Privosegtor (optic neuritis neuroprotective candidate) and Licaminlimab (dry eye disease program), upcoming registrational milestones (PIONEER-1, PIONEER-2, PIONEER-3 trials), and financial position (cash runway into 2H 2029). The disclosure focuses on operational and clinical progress—trial designs, efficacy/safety results, regulatory designations (FDA Breakthrough, EMA PRIME, SPA agreement)—rather than a discrete event like M\u0026A, executive change, or financial restatement. It is material because it updates investors on the status and timing of key value-driving clinical milestones and the company's pipeline advancement, which would affect a reasonable investor's assessment of the registrant's prospects.","company_name":"Oculis Holding AG","ticker":"OCSAW","filing_date":"2026-06-25","form":"6-K","submitted_at":null,"items":[{"id":11107,"accession_number":"0001193125-26-282715","item_number":"EX-99.1","item_title":"ocs-ex99_1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This exhibit is a corporate presentation (investor deck) dated June 2026 disclosing Oculis' clinical development pipeline, preclinical and Phase 2 trial data for Privosegtor (optic neuritis neuroprotective candidate) and Licaminlimab (dry eye disease program), upcoming registrational milestones (PIONEER-1, PIONEER-2, PIONEER-3 trials), and financial position (cash runway into 2H 2029). The disclosure focuses on operational and clinical progress—trial designs, efficacy/safety results, regulatory designations (FDA Breakthrough, EMA PRIME, SPA agreement)—rather than a discrete event like M\u0026A, executive change, or financial restatement. It is material because it updates investors on the status and timing of key value-driving clinical milestones and the company's pipeline advancement, which would affect a reasonable investor's assessment of the registrant's prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-25T20:02:39.848360+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":11107,"accession_number":"0001193125-26-282715","item_number":"EX-99.1","item_title":"ocs-ex99_1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This exhibit is a corporate presentation (investor deck) dated June 2026 disclosing Oculis' clinical development pipeline, preclinical and Phase 2 trial data for Privosegtor (optic neuritis neuroprotective candidate) and Licaminlimab (dry eye disease program), upcoming registrational milestones (PIONEER-1, PIONEER-2, PIONEER-3 trials), and financial position (cash runway into 2H 2029). The disclosure focuses on operational and clinical progress—trial designs, efficacy/safety results, regulatory designations (FDA Breakthrough, EMA PRIME, SPA agreement)—rather than a discrete event like M\u0026A, executive change, or financial restatement. It is material because it updates investors on the status and timing of key value-driving clinical milestones and the company's pipeline advancement, which would affect a reasonable investor's assessment of the registrant's prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-25T20:02:39.848360+00:00","company_name":"Oculis Holding AG","ticker":"OCSAW","filing_date":"2026-06-25"}]}